RxDoctor Payments Data

Lindsay Short

Family · Rochester, NYNPI 1508029828

Payments from drug & device makers

$5,494in general payments, 2019–2025

Across 240 payments — averaging $22.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$881
  • Astellas Pharma US Inc$874
  • Pfizer$421
  • Procept Biorobotics Corporation$419
  • AbbVie$409
  • Merck$344
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$5,14594%
  • Education$3496%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,494 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.

See all family providers in New York

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron212$187,721
MyrbetriqMirabegron161$114,196
Mirabegron ErMirabegron82$37,438
BotoxOnabotulinumtoxina20$20,741
Testosterone48$17,858
Tamsulosin Hcl792$13,400
XyostedTestosterone Enanthate13$11,258
Bcg (Tice Strain)Bcg Live17$11,046
Trospium Chloride186$9,603
Testosterone Cypionate92$5,147
Finasteride316$4,512
Methenamine Hippurate60$4,377
Solifenacin Succinate125$4,296
NitrofurantoinNitrofurantoin Macrocrystal71$4,287
Trospium Chloride ErTrospium Chloride22$3,858

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$881$187,721212 claims
Astellas Pharma US IncMyrbetriq$874$114,196161 claims
AbbVieBotox$409$20,74120 claims
Antares Pharma, Inc.Xyosted$132$11,25813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.

Other family in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →